These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29671113)

  • 1. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
    Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
    Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
    Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
    Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
    J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
    Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
    BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
    Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D
    JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
    Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
    JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
    Farias AJ; Du XL
    Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant therapy use among Appalachian breast cancer survivors.
    Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
    Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
    Toledo G; Ochoa CY; Farias AJ
    Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
    Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
    Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta-analysis.
    Finitsis DJ; Vose BA; Mahalak JG; Salner AL
    Psychooncology; 2019 Feb; 28(2):255-263. PubMed ID: 30511789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
    Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
    Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
    Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
    Farias AJ; Wu WH; Du XL
    BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Lambert LK; Balneaves LG; Howard AF; Gotay CC
    Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
    Woolpert KM; Schmidt JA; Ahern TP; Hjorth CF; Farkas DK; Ejlertsen B; Collin LJ; Lash TL; Cronin-Fenton DP
    Breast Cancer Res; 2024 Apr; 26(1):59. PubMed ID: 38589932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
    Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
    Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
    Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
    Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.